Zinexts at HIMSS 2026: Wrapping Up a Landmark Debut
Zinexts made its debut at the Healthcare Information and Management Systems Society (HIMSS) Conference and Exhibition, held 10-12 March 2026, in Las Vegas, USA.
HIMSS stands as one of the world’s most influential gatherings for health information and technology professionals, bringing together more than 25,000 industry leaders from 88 countries.
Zinexts was invited to participate as part of the Taiwan Excellence Pavilion, organized by the External Trade Development Council (TAITRA) and supported by the International Trade Administration, Ministry of Economic Affairs, Taiwan (TITA).
Zinexts Flagship Solutions
Under the theme “From Taiwan with Care”, Zinexts presented its latest innovations at the Taiwan Excellence Product Launch Event.
Zinexts highlighted two new technologies designed to bring greater automation and smarter solutions to clinical laboratories, helping improve efficiency and support more reliable diagnostic workflows.
- NeXgen™ 16HP — A fully automated sample-to-high-plex qPCR system designed to simplify molecular testing in clinical laboratories. It can detect up to 40 targets from a single sample, helping laboratories identify complex infectious diseases and oncology biomarkers more efficiently and with reliable clinical-grade performance.
- Zinexts DataVerse™ — AI-driven data management and analysis that transforms diagnostic results into actionable and personalized clinical insights. It includes advanced NGS data analysis compatible with major sequencing platforms, with offline capability for data security and privacy.
Dr. Hartmut Goette, General Manager of Zinexts Life Science Corp., emphasized that while clinicians today receive vast amounts of diagnostic data, meaningful insights remain limited. Zinexts designed its solutions to help laboratories deliver clear answers rather than just numbers, bringing more actionable information closer to the point of care and supporting the next era of molecular diagnostics.
The Power of Zinexts Technology
The real breakthrough lies in the integration of NeXgen™ 16HP and Zinexts DataVerse™. Together, they move beyond simply reporting diagnostic results by helping transform molecular data into comprehensive clinical reports tailored to individual patients.
This combined approach supports more effective and efficient patient care management. NeXgen™ 16HP delivers reliable automation from sample preparation to multiplex PCR results, while DataVerse™ extends the value of those results through advanced data interpretation and patient-focused insights, creating a seamless workflow from laboratory testing to clinical decision support.
Interpreting molecular findings and translating them into meaningful recommendations often requires significant expertise, time and infrastructure, that many healthcare systems may find difficult to maintain.
The integration of these technologies is designed to help bridging the gap, enabling laboratories to deliver clear, actionable information to clinicians and leading to faster and more informed clinical decisions.
What We Heard at HIMSS 2026
Over three days at HIMSS 2026, we engaged with partners, healthcare innovators, and industry professionals, gaining valuable insights into how molecular diagnostics and intelligent technology can better support patient care through more connected workflows.
If you represent a laboratory, hospital, or healthcare organization exploring how connected molecular diagnostics could support your clinical environment, we would be pleased to continue the conversation at info@zinexts.com.
